Tag: biotechnology

September 11, 2018

Cannabis Investment: Canadian Cannabis Stocks

The Canadian cannabis space is one of the hottest growing sectors. Are you interested in cannabis investment? Here's a look...
August 23, 2018

What Factors Impact Graphene Cost?

Despite its exciting applications, graphene is not currently widely used, and cost is a key reason why. Here's a look...
August 12, 2018

5 Top Weekly NASDAQ Biotech Stocks: Vericel Takes Top Spot

Vericel, AcelRx, Tetraphase Pharmaceuticals, KalVista and Infinity Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.
July 31, 2018

Innovate Biopharmaceuticals Enters into a Collaboration on Larazotide’s Effect on Improving the Microbiome of Children with EED with the University of Virginia School of Medicine

Innovate Biopharmaceuticals (NASDAQ:INNT) has announced a collaboration with James P. Nataro, MD, PHD, MBDA, the Benjamin Armistead Shepherd Professor and...
July 31, 2018

NanoSphere Health Sciences Partners with Delta 9 for Canadian Expansion

NanoSphere Health Sciences (CSE:NSHS), the biotechnology leader behind the patented NanoSphere Delivery System™, has entered into a partnership with Delta...
July 30, 2018

5 Private Longevity Research Stocks to Watch: From Calico to Genescient

Calico is just one longevity research company that promises to make major headlines in the longevity investing space.
July 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: resTORbio Leads the Pack

resTORbio, ADMA Biologics, Misonix, Novus Therapeutics and Innovate Biopharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.
July 23, 2018

Rubius Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rubius Therapeutics (NASDAQ:RUBY) has announced the closing of its initial public offering of 12 million shares of its common stock...
July 16, 2018

CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial

CytoDyn (OTCQB:CYDY) has announced that roughly 81 percent of patients that completed the 25-week CD02 pivotal trial with PRO 140...
July 15, 2018

5 Top Weekly NASDAQ Biotech Stocks: Arbutus on Top

Adamis Pharmaceutical, Juniper Pharmaceuticals, Anavex Life Sciences, Arbutus BioPharma and Soleno Therapeutics were last week's top gainers on the NASDAQ...